PremiumThe FlyOric Pharmaceuticals data ‘home run scenario,’ says JPMorgan Buy Rating for Oric Pharmaceuticals Driven by Promising ORIC-944 Study Results and Undervaluation Closing Bell Movers: Nvidia gains 4% on earnings, lifting other semis PremiumRatingsORIC Pharmaceuticals: Promising Growth Potential with Superior Safety Profile and Strong Financial Position Oric Pharmaceuticals price target raised to $22 from $21 at H.C. Wainwright ORIC Pharmaceuticals: A Promising Buy with Upcoming Data Catalysts and Competitive Safety Profile PremiumThe FlyOric Pharmaceuticals reports Q1 EPS (42c), consensus (50c) Oric Pharmaceuticals presents preclinical ORIC-944 data at AACR Oric Pharmaceuticals Expands Equity Incentive Plan for Growth 
